BiotechTube

RG2417 + Placebo

Phase 2Completed
0 watching 0 views this week⚡ Active
49
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Bipolar I Depression

Conditions

Bipolar I Depression

Trial Timeline

Nov 1, 2008 → Dec 1, 2010

NCT ID
NCT00812058

About RG2417 + Placebo

RG2417 + Placebo is a phase 2 stage product being developed by Repligen for Bipolar I Depression. The current trial status is completed. This product is registered under clinical trial identifier NCT00812058. Target conditions include Bipolar I Depression.

Hype Score Breakdown

Clinical
17
Activity
12
Company
7
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT00812058Phase 2Completed

Competing Products

20 competing products in Bipolar I Depression

See all competitors
ProductCompanyStageHype Score
OlanzapineEli LillyPhase 3
77
Valproate + Lithium + Risperidone + OlanzapineEli LillyPhase 3
77
Olanzapine + PlaceboEli LillyApproved
85
FK949EAstellas PharmaPhase 3
77
FK949EAstellas PharmaPhase 3
77
FK949E + PlaceboAstellas PharmaPhase 2/3
65
Escitalopram + Bupropion XLLupin LimitedPhase 3
77
OlanzapineEli LillyApproved
85
Olanzapine Hydrochloride + Lithium CarbonateEli LillyPhase 3
77
olanzapine + lithium + valproate + carbamazepineEli LillyPhase 3
77
OlanzapineEli LillyApproved
85
OlanzapineEli LillyPhase 3
77
LY2979165 + PlaceboEli LillyPhase 1
33
olanzapine + divalproex sodium + placeboEli LillyApproved
85
olanzapine + risperidoneEli LillyApproved
85
LY2979165 + placeboEli LillyPhase 1
33
Topiramate + PlaceboEli LillyApproved
85
olanzapineEli LillyPhase 3
77
Olanzapine + PlaceboEli LillyPhase 3
77
Brenipatide + PlaceboEli LillyPhase 2
52

Other Products from Repligen

RG1068 (Synthetic Human Secretin)Phase 3
74
RG1068 (Synthetic Human Secretin)Phase 3
74
RG1068 (synthetic human secretin)Phase 3
74
UridinePhase 2
49
RG1068 (Synthetic Human Secretin)Phase 2
49